<DOC>
	<DOCNO>NCT01610310</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetic ( PK ) profile , safety , tolerability peginterferon beta-1a ( BIIB017 ) deliver single-use autoinjector prefilled syringe ( PFS ) healthy volunteer support development autoinjector .</brief_summary>
	<brief_title>Peginterferon Beta-1a ( BIIB017 ) Autoinjector Pharmacokinetic Study Healthy Volunteers</brief_title>
	<detailed_description>This randomize , open-label , 2-sequence , 2-period crossover study conduct single site United States characterize PK profile , safety tolerability peginterferon beta-1a deliver autoinjector PFS . Participants randomize 1:1 ratio receive single dose peginterferon beta-1a Day 1 deliver either autoinjector PFS , follow single dose peginterferon beta 1a delivered device Day 22 . The total duration study participation 3 month participant . Participants complete follow-up visit Day 50 end treatment period .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Key 1 . Must body mass index ( BMI ) 19 29 kg/m^2 , inclusive , minimum body weight 50.0 kg Key 1 . History clinically significant laboratory abnormality , malignancy , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease 2 . Female subject pregnant breastfeed 3 . Any previous treatment prescription investigational pegylated drug . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>SC</keyword>
	<keyword>PEG</keyword>
	<keyword>Inteferon</keyword>
	<keyword>PK</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>PEGylated</keyword>
	<keyword>Autoinjector</keyword>
	<keyword>Injectable</keyword>
	<keyword>MS</keyword>
</DOC>